Collectively, these data suggest TAB2 as a new target for TRIM38 in NASH and indicate that TRIM38 can interact with TAB2 and promoted its protein degradation, thus attenuating the activation of the MAPK signaling pathway. This evidence concerns the gene TRIM38 and metabolic dysfunction-associated steatohepatitis.